SNFGE SNFGE
 
Thématique :
- Cancer colorectal (CCR)
Originalité :
Très original
Solidité :
A confirmer
Doit faire évoluer notre pratique :
Pas encore
 
 
Nom du veilleur :
Docteur Bernard DENIS
Coup de coeur :
 
 
Journal of the American Medical Association (JAMA)
  2016/06  
 
  2016 Jul 1;176(7):894-902.  
  doi: 10.1001/jamainternmed.2016.0960.  
 
  Population-Based Colonoscopy Screening for Colorectal Cancer: A Randomized Clinical Trial.  
 
  Bretthauer M, Kaminski MF, Løberg M, Zauber AG, Regula J, Kuipers EJ, Hernán MA, McFadden E, Sunde A, Kalager M, Dekker E, Lansdorp-Vogelaar I, Garborg K, Rupinski M, Spaander MC, Bugajski M, Høie O, Stefansson T, Hoff G, Adami HO; Nordic-European Initiative on Colorectal Cancer (NordICC) Study Group.  
  http://www.ncbi.nlm.nih.gov/pubmed/27214731  
 
 

 

MPORTANCE:

Although some countries have implemented widespread colonoscopy screening, most European countries have not introduced it because of uncertainty regarding participation rates, procedure-related pain and discomfort, endoscopist performance, and effectiveness. To our knowledge, no randomized trials on colonoscopy screening currently exist.

OBJECTIVE:

To investigate participation rate, adenoma yield, performance, and adverse events of population-based colonoscopy screening in several European countries.

DESIGN, SETTING, AND POPULATION:

A population-based randomized clinical trial was conducted among 94 959 men and women aged 55 to 64 years of average risk for colon cancer in Poland, Norway, the Netherlands, and Sweden from June 8, 2009, to June 23, 2014.

INTERVENTIONS:

Colonoscopy screening or no screening.

MAIN OUTCOMES AND MEASURES:

Participation in colonoscopy screening, cancer and adenoma yield, and participant experience. Study outcomes were compared by country and endoscopist.

RESULTS:

Of 31 420 eligible participants randomized to the colonoscopy group, 12 574 (40.0%) underwent screening. Participation rates were 60.7% in Norway (5354 of 8816), 39.8% in Sweden (486 of 1222), 33.0% in Poland (6004 of 18 188), and 22.9% in the Netherlands (730 of 3194) (P < .001). The cecum intubation rate was 97.2% (12 217 of 12 574), with 9726 participants (77.4%) not receiving sedation. Of the 12 574 participants undergoing colonoscopy screening, we observed 1 perforation (0.01%), 2 postpolypectomy serosal burns (0.02%), and 18 cases of bleeding owing to polypectomy (0.14%). Sixty-two individuals (0.5%) were diagnosed with colorectal cancer and 3861 (30.7%) had adenomas, of which 1304 (10.4%) were high-risk adenomas. Detection rates were similar in the proximal and distal colon. Performance differed significantly between endoscopists; recommended benchmarks for cecal intubation (95%) and adenoma detection (25%) were not met by 6 (17.1%) and 10 of 35 endoscopists (28.6%), respectively. Moderate or severe abdominal pain after colonoscopy was reported by 601 of 3611 participants (16.7%) examined with standard air insufflation vs 214 of 5144 participants (4.2%) examined with carbon dioxide (CO2) insufflation (P < .001).

CONCLUSIONS AND RELEVANCE:

Colonoscopy screening entails high detection rates in the proximal and distal colon. Participation rates and endoscopist performance vary significantly. Postprocedure abdominal pain is common with standard air insufflation and can be significantly reduced by using CO2.

 
Question posée
 
Quelles sont la faisabilité, l’adhésion de la population, le rendement et le risque d’un dépistage du cancer colorectal par coloscopie en Europe ?
 
Question posée
 
Le taux de participation variait énormément selon le pays de 23% aux Pays Bas à 61% en Norvège. Les douleurs abdominales post coloscopie étaient fréquentes en cas d’insufflation à l’air, significativement réduites en cas d’insufflation de CO2.
 
Commentaires

Cet article est le premier à rapporter les résultats préliminaires d’un essai contrôlé randomisé dont l’objectif principal est de démontrer l’efficacité du dépistage par coloscopie par rapport à l’absence de dépistage. On peut s’interroger sur le caractère éthique d’un bras contrôle sans dépistage dès lors qu’il a été  démontré avec le meilleur niveau de preuve possible que le dépistage par recherche de sang occulte dans les selles et par recto-sigmoïdoscopie permettait de réduire significativement la mortalité par cancer colorectal. Le taux de détection d’adénomes à haut risque était de 10%, nettement inférieur à celui des coloscopies réalisées pour test immunologique positif (> 30% dans le programme français).

 
www.snfge.org